title: Long-Term Real-Life Efficacy and Safety of Repeated Ozurdex® Injections and Factors Associated with Macular Edema Resolution after Retinal Vein Occlusion: The REMIDO 2 Study.
abstract: OBJECTIVE
  The objective was to study long-term real-life efficacy and safety of repeated Ozurdex® injections and factors associated with macular edema (ME) resolution after retinal vein occlusion.
  
  
  METHODS
  Patients with ME after retinal vein occlusion, receiving Ozurdex®, were included to assess the following endpoints: visual acuity and central retinal thickness, retreatment, number of injections, side effects and ME resolution. ME resolution was defined as permanent discontinuation of intravitreal injections (IVTs) for at least 6 months after the last IVT.
  
  
  RESULTS
  A total of 94 eyes were included with an average of 2.6 IVTs (max 6 IVTs). 58.6% of patients gained ≥15 letters and 51.1% of patients showed ME resolution. Among the resolved patients, 64.6% were treatment-naïve, 60.4% had branch retinal vein occlusion, and 78.1% gained ≥15 letters.
  
  
  CONCLUSIONS
  Ozurdex® seemed to be a valuable treatment which may allow to achieve long-term anatomical and functional improvements and ME resolution with a minimum number of IVTs.
authors.affiliation: Collectif P1.5, Mougins, France.
authors.forename: Stéphan
authors.initials: S
authors.lastname: Pommier
authors.forename: Franck
authors.initials: F
authors.lastname: Meyer
authors.forename: Sébastien
authors.initials: S
authors.lastname: Guigou
authors.forename: Tony
authors.initials: T
authors.lastname: Barthelemy
authors.forename: Fréderic
authors.initials: F
authors.lastname: Gobert
authors.forename: Christian
authors.initials: C
authors.lastname: Hajjar
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Merite
authors.forename: Eric
authors.initials: E
authors.lastname: Parrat
authors.forename: Hervé
authors.initials: H
authors.lastname: Rouhette
authors.forename: Fréderic
authors.initials: F
authors.lastname: Matonti
mesh_terms: D000368:Aged; D003907:Dexamethasone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000000981:diagnostic imaging* / Q000187:drug effects; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000175:diagnosis; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone